
Turing names R&D president
pharmafile | June 11, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | eliseo salinas, turing
Turing Pharmaceuticals has appointed life sciences executive and medical researcher Dr Eliseo Salinas to the company as president of R&D.
The former chief scientific officer for Shire Pharmaceuticals and Relmada Therapeutics has also headed R&D for Adolor and Stem Cells in the past, and is a trained psychiatrist and CNS specialist.
“We are pleased to welcome Eliseo Salinas to our leadership team,” says Turing founder and chairman Martin Shkreli. “Eliseo combines proven capabilities to bring important new treatments to patients and their physicians, with a deep understanding of the patient and physician communities.”
“I am excited to be joining Turing,” Salinas adds. “It is a special opportunity to be part of a dynamic young company with an important portfolio of assets in development, a strong management team and a great vision. I look forward to helping to accelerate Turing’s success and contribution to healthcare.”
Related Content

‘He was born this way’, Shkreli case becomes circus
Martin Shkreli’s Attorney, Benjamin Brafman, defended his client in a bizarre reference to a pop …

Martin Shkreli subpoenaed in US to testify over drug pricing
Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US …

Turing chief exec Martin Shkreli arrested
Turing chief executive Martin Shkreli has been arrested on a charge of securities fraud relating …






